Open AccessCytomegalovirus-vectored vaccines for HIV and other pathogens
Author(s) -
Peter A. Barry,
Jesse D. Deere,
Yujuan Yue,
William W.L. Chang,
Kimberli A. Schmidt,
Felix Wussow,
Flavia Chiuppesi,
Don J. Diamond,
Ellen E. Sparger,
Mark R. Walter,
Dennis J. Hartigan-O’Connor
Publication year - 2020
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002396
Subject(s) - virology , cytomegalovirus , immunology , immune system , immunity , biology , antigen , simian immunodeficiency virus , vector (molecular biology) , virus , viral disease , herpesviridae , recombinant dna , biochemistry , gene
: The use of cytomegalovirus (CMV) as a vaccine vector to express antigens against multiple infectious diseases, including simian immunodeficiency virus, Ebola virus, plasmodium, and mycobacterium tuberculosis, in rhesus macaques has generated extraordinary levels of protective immunity against subsequent pathogenic challenge. Moreover, the mechanisms of immune protection have altered paradigms about viral vector-mediated immunity against ectopically expressed vaccine antigens. Further optimization of CMV-vectored vaccines, particularly as this approach moves to human clinical trials will be augmented by a more complete understanding of how CMV engenders mechanisms of immune protection. This review summarizes the particulars of the specific CMV vaccine vector that has been used to date (rhesus CMV strain 68-1) in relation to CMV natural history.